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Abstract  
 
Infantile haemangiomas are the most common tumour of infancy. Whilst the 
majority are left untreated to involute spontaneously, residual skin changes 
commonly occur, particularly in superficial haemangiomas. The current first line 
treatment for problematic lesions is oral propranolol, however due to the risk of 
systemic adverse effects, the use of off-label topical preparations has recently been 
investigated. Our systematic review was conducted in accordance with PRISMA 
guidelines. Four databases were searched to identify original articles evaluating the 
use of topical propranolol as the primary therapy for infantile haemangiomas. 
Twelve articles with a total of 597 patients and 632 haemangiomas were included. 
Three topical propranolol preparations were used, creams, ointments and gels, and 
were all prepared by local pharmaceutical laboratories. The concentration of 
propranolol ranged from 0.5% to 5%. Treatment duration ranged from two weeks to 
16.5 months. Overall, 90% of lesions improved following the initiation of topical 
propranolol. A good or excellent response, defined as a reduction in size of at least 
50%, was seen in 59% of lesions. Earlier initiation of treatment (less than 3 months of 
age) was associated with improved outcomes. No systemic adverse effects were 
reported. Minor local reactions were seen in 1.3% of patients. Topical propranolol is 
safer than oral propranolol, though may be less effective. Topical propranolol may 
be more suitable for patients with small, superficial haemangiomas at risk of 
cosmetic sequelae, where the cosmetic or symptomatic impact does not warrant 
oral propranolol treatment.  
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Introduction 
 
Infantile haemangiomas are the most common tumours of infancy. They are benign 
vascular neoplasms with an incidence of 4-10%1,2. They are more common in female, 
Caucasian and low-birth weight infants3. The lesions are rarely detectable at birth 
but become evident during a proliferative phase after four weeks3 and continue to 
grow rapidly until a mean age of 3.2 months4. Rapid vasculogenesis and angiogenesis 
are followed by spontaneous involution beginning at around one year of age4. Fifty 
percent spontaneously regress by age 5 years, 70% by age 7 years5. Infantile 
haemangiomas may be classified according to their depth; superficial, located in the 
upper dermis (and therefore visible on the skin), deep, extending to subcutaneous 
fascia, or mixed3. They can occur anywhere on the body but are most commonly 
found on the head and neck3. The diagnosis of infantile haemangiomas is clinical. 
There are various scoring systems that can be used to assess severity and 
complications, such as the Haemangioma Severity Scale6. Treatment outcomes can 
be evaluated using scoring systems based on changes in colour, texture and volume, 
for example the Achauer system, which grades reduction in lesion size as poor (0-
25%), fair (26-50%), good (51-75) or excellent (76-100%)7.  
 
Ulceration is the most common complication of infantile haemangiomas, with an 
incidence of up to 16% in patients referred to tertiary centres8. Peri-orbital 
haemangiomas can lead to visual impairment whilst paraglottic or tracheal lesions 
can cause life-threatening airway obstruction6. Facial haemangiomas, particularly 
around the nose and lip, can cause permanent disfigurement6. Due to the risk of 
complications, 10-15% of infantile haemangiomas require treatment9. The majority 
of haemangiomas are left untreated to involute spontaneously but residual skin 
changes such as telangiectasia, fibrofatty tissue and skin laxity commonly occur, 
particularly in superficial haemangiomas6,10. Previously, corticosteroids were the 
treatment of choice, with alternatives such as interferon-alpha and vincristine9. The 
beneficial effect of oral propranolol on infantile haemangiomas was discovered 
incidentally in 200811.  Its mechanism of action is not fully understood, but may be 
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due to inhibition of angiogenesis, pericyte-mediated vasoconstriction, induction of 
endothelial cell apoptosis and/or inactivation of the renin-angiotensin system12. Due 
its superior efficacy compared to the aforementioned medications, oral propranolol 
is now considered first line13. Oral propranolol administration carries the risk of 
systemic effects such as hypoglycaemia, bradycardia, hypotension, bronchospasm 
and electrolyte disturbance, and close monitoring (which may involve hospital 
admission) is required during treatment initiation13. Adverse effects have been 
reported to occur in 31% of patients treated with oral propranolol at the empirical 
cardiovascular dose, although commonly these are sleep disturbance and 
acrocyanosis; serious adverse effects are much rarer13,14. Lower dose oral 
propranolol has been shown to cause fewer adverse effects15. 
 
Localised methods of drug delivery, including topical and intralesional application, 
have been investigated and trialled. The 2015 recommendations from the European 
expert group state that as there is insufficient information regarding the safety and 
efficacy of topical betablockers (which are currently off-label), they cannot be 
recommended as standard treatment, but they have a potential for future use in 
small, superficial haemangiomas13. Topical application allows drug delivery directly 
to the diseased area, avoiding first pass metabolism. It has been suggested that 
topical propranolol acts to suppress haemangioma proliferation by reducing the 
levels of vascular endothelial growth factor (VEGF)16. For superficial haemangiomas, 
which do not extend beyond the papillary dermis, the local accumulation of 
propranolol without significant systemic absorption may be an advantage17. The 
optimal preparation, dosage and duration of topical propranolol are currently 
unknown. The aim of this systematic review is to assess the efficacy and safety of 
topical propranolol in the treatment of infantile haemangiomas.  
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Methods  
 
Search strategy  
The review was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (‘PRISMA’) pro forma (Fig. 1). Four databases 
were searched; EMBASE (1947 – present), MEDLINE (1946 – March week 3 2017), 
PubMed (1966-present) and Cochrane Library (March 2017).  The search terms were 
split into three categories and combined using “AND”, individual search terms 
performed within each category were combined using “OR”. The first category 
included “adrenergic beta-antagonist”, “beta-antagonist”, “beta blocker” and 
“propranolol”. The second category contained “haemangioma”, “hemangioma” and 
“vascular malformation”.  The third category contained “topical” and “transdermal”. 
The search was up to date as of March 2017. 
 
Inclusion and Exclusion Criteria 
Original articles evaluating topical propranolol as the primary therapy for treating 
infantile haemangiomas were included. Articles written in a foreign language were 
only included if a suitable translation was found. Articles not reporting a clinical 
outcome were excluded. Meta-analyses, review articles, case studies, non-human 
studies and small studies (with fewer than five patients) were excluded.  
 
Data Collection 
Three authors (A.P., S.R. and R.M.) independently reviewed the articles identified. 
Articles were screened by title and abstract and those deemed relevant were 
reviewed in full text and selected or rejected based on the inclusion and exclusion 
criteria. Data extraction was performed by two authors (A.P. and S.R.) and compiled 
and analysed in Microsoft Excel®.  This included the number of patients, patient 
demographics, the site and size of the haemangioma, the preparation, concentration 
and dosing of propranolol, the duration of treatment, the method of measuring 
response, the response rate, the number of patients with rebound after cessation of 
treatment and any adverse effects. Overall response rate was defined as the 
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percentage of lesions showing improvement with treatment. A good or excellent 
response was defined as the percentage of lesions with a more than 50% reduction 
in size, as specified by the Achauer system7. Where possible, data was combined to 
find overall values, however not all articles included data on all of these measures. 
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Results 
 
Database searching identified 454 articles, and one article was identified from a 
reference list (Fig. 1). Subsequently 54 articles were assessed in full text. After 
inclusion and exclusion criteria were applied, 12 articles with a total of 597 patients 
and 632 haemangiomas were selected for review (Table 1).  
 
Insert Figure 1. 
 
Patient characteristics 
65% of patients were female. The age at treatment initiation ranged from 3 weeks to 
33 months, with a mean of 4.5 months. Three studies included patients with mixed 
(n=30) or deep (n=6) haemangiomas, eight studies involved superficial 
haemangiomas and one study did not specify the depth. The lesions were located all 
over the body, including the head and neck and anogenital region. The 
haemangioma size ranged from 0.5cm2 to over 10cm2.  
 
Treatment regimen 
Three topical propranolol preparations were used, creams, ointments and gels, all 
prepared by local pharmaceutical laboratories. Propranolol concentrations ranged 
from 0.5% to 5% (Table 1). In seven out of twelve studies, treatment was stopped 
under the following circumstances; disappearance of the lesion, no response to 
treatment, appearance of a deep component or adverse effects. In these instances, 
treatment duration ranged from two weeks to 16.5 months (Table 1). The remaining 
five studies specified treatment durations, ranging from 2 weeks to 10 months. 
 
Five studies performed pre-treatment screening including echocardiography, 
electrocardiography, blood pressure, liver and kidney function tests and blood 
glucose levels. Five studies treated patients in hospital for the first 24 - 48 hours and 
monitored vital signs and blood glucose levels before and after topical application.  
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Insert Table 1. 
 
Evaluating response to treatment 
All studies used clinicians to evaluate the treatment response, the number of 
clinicians involved was not specified. Seven studies used photography to document 
the response and change in size and two used Doppler ultrasonography. The 
Achauer grading system (n=3) or similar method (n=6) where the grade of response 
(poor, moderate, good or excellent) was determined by the percentage reduction in 
size were used to measure response. Three studies used a haemangioma score that 
took into account colour, consistency and size.  
 
Reduction in haemangioma size 
Across all studies, an improvement in 90% of haemangiomas was seen at the end of 
the treatment period (543 out of 602 lesions – 30 lost to follow-up). Ten studies (389 
lesions) specified a reduction in size of at least 50% (a good or excellent response). 
This was seen in 59% of lesions (n=228). The overall response rate ranged from 67% 
to 100%. The good or excellent response rate ranged from 42% to 86%. The highest 
good or excellent response rate of 86% was obtained using a 0.5% nano-propranolol 
hydrogel applied three times daily until 90% of the lesion had disappeared (for up to 
11 months). In this study, propranolol was incorporated into nanoparticles of 
colloidal silicon dioxide with the aim of increasing skin penetration18. The lowest 
response rate of 42% was obtained using a 3% propranolol gel applied three times a 
day for three months16.  
 
Speed of response 
Five studies investigated the onset of treatment response. Within the first month of 
treatment, fading, softening and early regression was noted. In patients with a size 
reduction of over 50%, change in colour from red to purple and softening of the 
lesion was seen within 7 days of treatment initiation, and this was followed by a 
progressive reduction in size17. 
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Optimum dosage of propranolol 
The application frequency and concentration of propranolol did not affect outcome 
(Figs 2-3). When topical propranolol was applied twice a day, the overall response 
rate was 91% (range 66-100%) and 55% (range 44-75%) of lesions had a good or 
excellent response . For three times daily applications, the overall response and good 
or excellent response rates were 89% (range 81-95%) and 62% (range 42-86%) 
respectively. No studies directly compared the frequency of application. One study 
did not identify a significant difference between 2.5% and 5% propranolol gel, both 
were better than placebo17.  
 
Insert Figure 2. 
 
Insert Figure 3. 
 
Rebound growth 
Six studies (508 patients) reported the occurrence of rebound growth, which 
occurred in 1.2% (n=6) up to five months after cessation of treatment. The 
characteristics of the lesions that exhibited rebound growth were not specified in the 
studies. 
 
Adverse effects 
In the eleven studies (600 patients) that documented adverse effects, no systemic 
effects attributable to topical propranolol were recorded. Minor localised side 
effects, such as itching and erythema, were seen in 1.3% (n=8) (Table 2). Two studies 
included low-weight preterm infants who did not experience an increased 
complication rate or any systemic side effects19,20.  
 
Insert Table 2. 
 
Oral, topical and intralesional propranolol 
One study compared oral (n=15), topical (n=15) and intralesional propranolol 
(n=15)21. A higher proportion of haemangiomas improved with oral compared to 
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topical and intralesional treatment (86.7% vs. 66.7% and 53.3% respectively)21. The 
response was faster in the oral group, with an initial response seen in 2-4 weeks 
(mean 2.67 weeks) compared to 3-8 weeks (mean 5.87 weeks) in the topical group. 
Treatment duration was shorter in the oral group compared to the topical group (3-9 
months, mean 5.13 months, vs. 5-10 months, mean 7.47 months)21. In the oral 
group, one patient suffered a syncopal attack and 3 patients had a significantly lower 
heart rate and diastolic blood pressure. No systemic effects were observed with 
topical treatment21.  
 
Depth of lesion and treatment initiation  
A better response for superficial compared to mixed or deep haemangiomas was 
seen in one study22. Two studies found an improved response when treatment was 
initiated earlier19,23. One study achieved an excellent response in 52% of patients 
aged between 3-9 weeks at treatment initiation, compared to 33% aged 10-20 weeks 
and 0% aged 22-52 weeks23. 
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Discussion 
 
Oral propranolol is currently the first line treatment for infantile haemangiomas13, 
but alternative, topical beta-blocker treatments are being explored.  We identified 
12 studies published between 2012 and 2017 in which topical propranolol was the 
primary treatment for infantile haemangiomas in over 600 patients, with no 
reported systemic side effects. Overall, 90% of lesions improved following the 
initiation of topical propranolol. A good or excellent response was seen in 59% of 
lesions. Other studies have shown that patients treated with oral propranolol had a 
response rate of 98%14. In patients with small, superficial haemangiomas, the risks of 
systemic treatment with oral propranolol may outweigh the benefits. Retrospective 
studies of untreated haemangiomas have demonstrated high rates of cosmetic 
sequelae10,24. A lower risk, less efficacious treatment with topical propranolol may 
therefore be a good option in these cases.  
 
Treatment response, regimens and rebound 
Superficial haemangiomas responded well to treatment unlike mixed or deep 
haemangiomas22,23. The size of the lesion did not affect the outcome.20,25,26 One 
study reported that larger lesions (median 3cm2) had better outcomes compared to 
a smaller lesion group (median 1cm2)27; the authors theorised that reduced surface 
interface area of small lesions led to decreased topical efficacy27. Starting topical 
propranolol treatment early (under 3 months of age) was shown to improve 
response rates19,23,25. 
 
Heterogeneous concentrations and preparations were used in each study, making 
comparisons between them difficult, however there was no evidence to suggest that 
higher concentration preparations improved response rates17. The duration of 
treatment varied, some studies reporting outcomes as early as 2 weeks and others 
continuing treatment until the desired effect was achieved (up to 16.5 months). This 
could in part explain the varying response rates seen in different studies. Compared 
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to oral propranolol, topical treatment may need to be continued for longer in order 
to achieve the same effect21. 
 
Rebound growth was observed in 1.2% of cases and up to five months after the 
cessation of treatment. This figure may be unreliable as not all studies continued 
follow-up after treatment was stopped or for sufficient lengths of time (less than five 
months).  
 
Measuring response 
The method of measuring response was variable and grading was largely subjective 
introducing the potential for bias and complicating the definition of efficacy. The 
outcome measures were often subjective, and although similar, did not follow a 
standardised approach. Pooling data to obtain an overall response rate may 
therefore be misleading. 
 
Adverse effects 
Our review of 600 patients found topical propranolol to be a safe and effective 
treatment for infantile haemangiomas with no reported systemic side effects. 
Although high concentrations of topical propranolol are absorbed and retained by 
the skin28, when serum levels of propranolol were measured after topical application 
in 20 infants, they were always below the measureable range (<20ng/mL, 
therapeutic range 50-300ng/mL)20. This could explain why the low systemic adverse 
effect profile was encountered. 
 
Oral propranolol and other beta blockers 
Oral propranolol has increased efficacy and works faster than topical propranolol21, 
it also has an increased incidence of systemic adverse effects14. In vivo animal 
studies comparing the concentration-time profiles in the dermis for oral vs. topically 
applied propranolol found that the peak concentration was over 300 times higher 
following topical administration17. In addition, orally administered propranolol was 
eliminated from the skin quickly17. In vitro and in vivo human studies have shown 
that a much smaller proportion of topical propranolol is absorbed into the 
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bloodstream28,29. The increased efficacy of oral vs. topical propranolol could be 
explained by a combination of local and systemic mechanisms of action. 
 
Due to the availability of topical timolol, a common ophthalmic solution, more 
studies have reported on the use of topical timolol instead of topical propranolol30–
32. A meta-analysis identified an 83% response rate in superficial infantile 
haemangiomas treated with topical timolol33. Sleep disturbance and symptomatic 
bradycardia following initiation were the only reported systemic adverse effects in 
three patients33,34. In vitro analysis of the permeation of beta-blockers through the 
human epidermal membrane revealed that propranolol was ten times more 
permeable than timolol35. Whilst this is therapeutically advantageous, it may 
increase the risk of localised adverse effects.  
 
Limitations 
The high number of variables between studies makes reliable comparisons difficult. 
There is a lack of standardisation in the treatment regimes, with significant variability 
in the preparation and dosing. The age at treatment initiation could have affected 
the outcomes, as earlier treatment initiation was associated with improved 
outcomes. Most of the included studies were cohort studies. Of the two randomised 
trials17,21, only one included a placebo-controlled group17, which is particularly 
important as infantile haemangiomas are known to involute spontaneously.  
 
Future Trials 
There is a need for high quality randomised control trials to establish the viability of 
topical propranolol for the treatment of infantile haemangiomas. We suggest a focus 
on patients with small, superficial haemangiomas who would otherwise be 
untreated leaving the possibility of lifelong scarring or skin discolouration. As no 
benefit was found with three times daily application or higher concentration 
preparations, a twice daily application of a lower dose, e.g. 2%, would seem 
appropriate initially. Once the benefit of topical propranolol vs. placebo has been 
established, the preparation, dosing and treatment regimen could be analysed in 
comparative trials. 
 14 
Conclusions 
 
Topical propranolol is a treatment option for infantile haemangiomas and 
preliminary evidence suggests that it is effective and safe. It may be particularly 
useful in patients with small superficial haemangiomas, where the cosmetic or 
symptomatic impact does not warrant oral propranolol treatment.  
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Table 1. 
Study Preparation Dose Frequency Duration % of lesions 
with 
improvement 
% of 
lesions 
with good 
or 
excellent 
response 
Kunzi-Rapp 
201219 
Prospective 
cohort 
1% 
propranolol 
ointment 
Thin layer – 
around 15μg 
propranolol / 
cm2 
Twice daily Up to 16.5 
months 
91% (n=59/65) Not specified 
Wang et al. 
201222 
Prospective 
cohort 
3% 
propranolol 
gel 
Not specified Three times 
daily 
1 – 10 
months 
92% (n=47/51) 57% (n=29/51) 
Xu et al. 201225 
Retrospective 
cohort 
1% 
propranolol 
ointment 
Dependant 
on size of 
lesion 
Three times 
daily 
5 – 59 
weeks, 
average 21 
weeks 
90% (n=25/28) 57% (n=16/28) 
Bonifazi et al. 
201323  
Prospective 
cohort 
1% 
propranolol 
cream 
Maximum 
daily dose not 
exceeding 
2mg/kg 
Twice daily 4 – 6 
months 
81% (n=48/59)* 44% (n=26/59) 
Zaher et al. 
201321 
Randomised 
single-blind 
trial 
1% 
propranolol 
ointment 
Not specified Twice daily 5 – 10 
months, 
average 7.5 
months 
67% (n=10/15) 53% (n=8/15) 
Kovačević et al. 
201436 
Retrospective 
cohort 
1% 
propranolol 
cream 
Not specified Twice daily 10 months 100% (n=8/8) 75% (n=6/8) 
Schneider et al. 
201420 
Retrospective 
cohort 
1% 
propranolol 
gel 
1-2mm layer 
under 
occlusive 
dressing for 2 
hours 
Twice daily 12 weeks 99% (n=147/148) Not specified 
Chen et al. 
201537 
Retrospective 
cohort 
0.5% nano-
propranolol 
hydrogel 
2ml / cm2 Three times 
daily 
2 weeks – 
11 months 
86% (n=43/50) 86% (n=43/50) 
Tang et al. 
201516 
Prospective 
cohort 
3% 
propranolol 
gel 
Not specified Three times 
daily 
3 months 82% (n=27/33) 42% (n=14/33) 
Zhou et al. 
201417 
Randomised 
double-blind 
placebo-
controlled trial 
2.5% and 5% 
propranolol 
gels 
2mg / cm2 for 
2.5% gel or 
4mg / cm2 for 
5% gel 
Twice daily 2 weeks 2.5% group: 100% 
(n=15/15) 
 
5% group: 93% 
(n=14/15) 
2.5% group: 
60% (n=9/15) 
 
5% group: 73% 
(n=11/15) 
Mashiah et al. 
201727 
Retrospective 
cohort 
4% 
propranolol 
gel 
For lesion size 
of 5cm2 – 
6mg 
propranolol 
Twice daily 3 – 16 
months 
(mean 8 
months) 
83% (n=62/75) 57% (n=43/75) 
Wang et al. 
201726 
Prospective 
cohort 
2% 
propranolol 
cream 
Not specified Three times 
daily 
Until the 
lesion 
disappeare
d or 8 
months 
95% (n=38/40) 58% (n=23/40) 
*30 patients lost to follow-up. 
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Table 2. 
Study Adverse effect Number of 
patients 
Propranolol preparation Management 
Wang et al. 2012 22 Redness 3 3% propranolol gel three 
times daily 
Resolved 
spontaneously 
Kunzi-Rapp 2012 19 Itching 1 1% propranolol ointment 
twice daily 
Not specified 
Chen et al. 2015 37 Itching  2 0.5% nano-propranolol 
hydrogel twice daily 
None 
Mashiah et al. 2017 27 Irritation and 
redness 
2 4% propranolol gel twice 
daily 
Not specified 
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Legends 
 
Figure 1: Summary of the article selection process. 
 
Figure 2: The response rate for different frequencies of application of topical propranolol (pooled 
data). A good or excellent response rate was defined as a reduction in size of over 50%. (BD – twice a 
day, TDS – three times a day) 
 
Figure 3: The response rate for different concentrations of topical propranolol (pooled data). A good 
or excellent response rate was defined as a reduction in size of over 50%.  
 
Table 1: Propranolol preparation, administration and response rate. A good or excellent response was 
defined as more than a 50% reduction in haemangioma size. 
 
Table 2: Adverse effects. 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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